Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

Keyphrases

• Randomized Controlled Trial 100%
• Once-weekly 100%
• Growth Hormone Deficiency 100%
• Somapacitan 100%
• Once-daily 40%
• Norditropin® 40%
• Adverse Events 30%
• Standard Deviation Score 30%
• Growth Hormone 20%
• Growth Factors 20%
• Insulin-like 20%
• Injection Site Reaction 20%
• Treatment Satisfaction 20%
• Antigrowth 20%
• Treatment Satisfaction Questionnaire for Medication 20%
• Headache 10%
• Female Patients 10%
• Male Patients 10%
• Clinically Significant 10%
• Tolerability 10%
• Fixed-dose Combination 10%
• Change in Treatment 10%
• Once-weekly Administration 10%
• Local Tolerability 10%
• Nasopharyngitis 10%
• Local Treatment 10%
• Safety Issues 10%
• Score Level 10%
• Adult GH Deficiency 10%
• Daily Growth Hormone 10%
• Albumin Binding 10%
• Growth Hormone Derivative 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Randomized Controlled Trial 100%
• Growth Hormone Deficiency 100%
• Somapacitan 100%
• Human Growth Hormone 40%
• Adverse Event 30%
• Tolerability 20%
• Somatomedin C 20%
• Injection Site Reaction 20%
• Growth Hormone Antibody 20%
• Headache 10%
• Growth Hormone 10%
• Rhinopharyngitis 10%
• Growth Hormone Derivative 10%